The US indication for sacituzumab govitecan for use in bladder cancer, specifically metastatic urothelial cancer, is being withdrawn. This decision follows a negative trial, although the potential for targeting TROP2 in bladder cancer treatment is still considered to have potential. The withdrawal affects the drug's approval status for this particular use, with implications for nursing and patient care.